Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Jul 15;8(7):e108.
doi: 10.1002/hem3.108. eCollection 2024 Jul.

Recommendations for diagnosis, treatment, and prevention of iron deficiency and iron deficiency anemia

Affiliations

Recommendations for diagnosis, treatment, and prevention of iron deficiency and iron deficiency anemia

Achille Iolascon et al. Hemasphere. .

Abstract

Iron is an essential nutrient and a constituent of ferroproteins and enzymes crucial for human life. Generally, nonmenstruating individuals preserve iron very efficiently, losing less than 0.1% of their body iron content each day, an amount that is replaced through dietary iron absorption. Most of the iron is in the hemoglobin (Hb) of red blood cells (RBCs); thus, blood loss is the most common cause of acute iron depletion and anemia worldwide, and reduced hemoglobin synthesis and anemia are the most common consequences of low plasma iron concentrations. The term iron deficiency (ID) refers to the reduction of total body iron stores due to impaired nutrition, reduced absorption secondary to gastrointestinal conditions, increased blood loss, and increased needs as in pregnancy. Iron deficiency anemia (IDA) is defined as low Hb or hematocrit associated with microcytic and hypochromic erythrocytes and low RBC count due to iron deficiency. IDA most commonly affects women of reproductive age, the developing fetus, children, patients with chronic and inflammatory diseases, and the elderly. IDA is the most frequent hematological disorder in children, with an incidence in industrialized countries of 20.1% between 0 and 4 years of age and 5.9% between 5 and 14 years (39% and 48.1% in developing countries). The diagnosis, management, and treatment of patients with ID and IDA change depending on age and gender and during pregnancy. We herein summarize what is known about the diagnosis, treatment, and prevention of ID and IDA and formulate a specific set of recommendations on this topic.

PubMed Disclaimer

Conflict of interest statement

Patricia Aguilar Martinez: Nothing to Disclose. Dorine Swinkels: Nothing to Disclose. Sule Unal: Nothing to Disclose. Fabiana Busti: Nothing to Disclose. Myka Sanchez: Co‐Founder of SME BLOODGENETICS SL (a genetic company www.bloodgenetics.com); Participation in 2 clinical trials one for IRIDA (KEROS THERAPEUTICS), one for atransferrinemia (SanquinBlood Netherland). Achille Iolascon: Nothing to Disclose. Ali Taher—Outside Work: Novartis Pharmaceuticals: Consultancy, Research funding; Bristol‐Myers Squibb (Celgene): Consultancy, Research funding; Ionis Pharmaceuticals: Consultancy, Research Funding; Vifor: Consultancy, Research Funding; Agios: Consultancy. Rayan Bou Fakhredin: Nothing to Disclose. Graça Porto: Nothing to Disclose. Immacolata Andolfo: Nothing to Disclose. Roberta Russo: Nothing to Disclose. Martina Muckenthaler Silence Therapeutics PLC, Editorial Board/Blood Journal/HemaSphere. Malcolm. G. Munro: Consultancies Pharmacosmos, Vifor, Daichi‐Sankyo, Shield Therapeutics, Myovant, Abbvie; Immediate Past Chair, FIGO Menstrual Disorders Committee. Tomas Ganz: shareholder and scientific advisor of Intrinsic LifeSciences, and consultant for Ionis Pharmaceuticals, Disc Medicine, Silence Therapeutics, Chugai, Vifor, Akebia, Dexcel, and Avidity Bio.

Figures

Figure 1
Figure 1
Recommendations and relative consensus.
Figure 2
Figure 2
Iron deficiency (ID) diagnosis. Flow chart showing the crucial steps to make a diagnosis of ID.
Figure 3
Figure 3
Iron deficiency anemia (IDA) diagnosis. Flow chart showing the crucial steps to make a diagnosis of IDA.
Figure 4
Figure 4
Management of adult patients with iron deficiency (ID)/iron deficiency anemia (IDA). Flow chart showing the crucial steps to manage adult patients with ID/IDA. AUB, abnormal uterine bleeding; FIT, fecal immunochemical testing; HMB, heavy menstrual bleeding; GI, gastrointestinal; ID, iron deficiency; IDA, iron deficiency anemia; IRT, iron replacement therapy. *Oral IRT may interfere with colon preparation of colonoscopy by causing constipation. **May be delayed in elderly un‐fit populations or those with severe co‐morbidities, or CT cholangiography may be an alternative to colonoscopy.
Figure 5
Figure 5
Treatment of iron deficiency (ID)/iron deficiency anemia (IDA) in adult patients. Flow chart showing the possible therapeutic options in adult patients with ID/IDA.

References

    1. Nemeth E, Ganz T. Hepcidin and iron in health and disease. Annu Rev Med. 2023;74:261‐277. 10.1146/annurev-med-043021-032816 - DOI - PMC - PubMed
    1. Lo JO, Benson AE, Martens KL, et al. The role of oral iron in the treatment of adults with iron deficiency. Eur J Haematol. 2023;110:123‐130. 10.1111/ejh.13892 - DOI - PMC - PubMed
    1. Koleini N, Shapiro JS, Geier J, Ardehali H. Ironing out mechanisms of iron homeostasis and disorders of iron deficiency. J Clin Invest. 2021;131:e148671. 10.1172/JCI148671 - DOI - PMC - PubMed
    1. Camaschella C. Iron‐deficiency anemia. N Engl J Med. 2015;372:1832‐1843. 10.1056/NEJMra1401038 - DOI - PubMed
    1. Peyrin‐Biroulet L, Williet N, Cacoub P. Guidelines on the diagnosis and treatment of iron deficiency across indications: a systematic review. Am J Clin Nutr. 2015;102:1585‐1594. 10.3945/ajcn.114.103366 - DOI - PubMed